Sign inJoin waitlistJoin the waitlist

Katherine Tkaczuk

Director, Breast Evaluation and Treatment Program · University of Maryland School of Medicine Marlene and Stewart Greenebaum Cancer Center

Credentials: · ·

History

Breast Evaluation and Treatment Program · University of Maryland School of Medicine Marlene and Stewart Greenebaum Cancer Center
Present
University of Maryland School of Medicine
Present

University of Maryland Cancer Center; Veterans Administration Medical Center
1989–1992
St. Agnes Hospital
1987–1989
St. Agnes Hospital
1986–1987
Wroclaw Medical Academy, Wroclaw, Poland, Akademia Medyczna Im. Piastow Slaskich we Wroclawiu
1978–1984
Wroclaw Medical Academy, Wroclaw, Poland, Akademia Medyczna Im. Piastow Slaskich we Wroclawiu
1978–1984

Research

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast…
Journal of Clinical Oncology · 2003 · 931 citations
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a…
Journal of Clinical Oncology · 2001 · 493 citations
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Clinical Cancer Research · 2020 · 206 citations

Steven Feigenberg
15 papers
Susan Kesmodel
11 papers
Elizabeth Nichols
10 papers · 1 as a resident
EB
Emily Bellavance
9 papers
PR
Paula Rosenblatt
9 papers
Saranya Chumsri
7 papers
Sally Cheston
6 papers
DV
David Vanecho
4 papers
Jason Molitoris
4 papers · 4 as a resident
ME
Merrill Egorin
4 papers
Randi Cohen
4 papers
Robert Buras
4 papers

Clinical trials

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Principal investigator · Recruiting · Phase 1
A&G Pharmaceutical Inc.
2022–2026
1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer
Principal investigator · Terminated
University of Maryland, Baltimore
2014–2017
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Principal investigator · Terminated · Phase 2
University of Maryland, Baltimore
2014–2016
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
Principal investigator · Terminated · Phase 2
University of Maryland, Baltimore
2012–2016